Croda International Dips On Sale Of Its Bio-based Business But Still Rides High For 2021

0
Croda International Dips On Sale Of Its Bio-based Business But Still Rides High For 2021
sergeitokmakov / Pixabay

“Croda International Plc (LON:CRDA)’s share price has dipped on the news that it’s selling its bio-based industrial business to US firm Cargill Velocity Holdings for £778m. Given the review of this part of the business, a sale had been on the cards, so rather than the strategic direction of the Yorkshire based company, it may have been the price tag which disappointed some investors, with expectations that it could have clinched an even higher price tag.

Get The Full Walter Schloss Series in PDF

Get the entire 10-part series on Walter Schloss in PDF. Save it to your desktop, read it on your tablet, or email to your colleagues.

Q3 2021 hedge fund letters, conferences and more

Greenlight Beat The S&P In Q4: Here Are The Fund’s Biggest Winners

David Einhorn Greenlight CapitalDavid Einhorn's Greenlight Capital funds were up 11.9% for 2021, compared to the S&P 500's 28.7% return. Since its inception in May 1996, Greenlight has returned 1,882.6% cumulatively and 12.3% net on an annualized basis. Q4 2021 hedge fund letters, conferences and more The fund was up 18.6% for the fourth quarter, with almost all Read More

Croda International's Shares Fall

The 1.2% fall in early trading is a minor dent in a spectacular performance for Croda over 2021. It’s one of the FTSE 100 biggest risers, climbing 48% over the year, riding high on a surge of success. It reported some cracking record results for the first half in the summer and said annual profit would be well ahead of expectations. Broker upgrades on the stock also sent the share price soaring. The extent to which Croda is benefiting from the ongoing vaccine boom has become clear over recent months and it’s down to its investment in innovative technologies. It supplies lipid nanoparticles for Pfizer Inc. (NYSE:PFE)’s mRNA technology and given the demand for booster jabs, that area of Life Sciences is bounding ahead. Although revenues from Pfizer may wane, there is expectation that there will be growing customer demand for a broader range of use of its products in medical treatments like oncology. Recovery in consumer markets has also helped its personal care sector which focuses on ingredients for skin, hair, and cosmetic products and the focus on sustainability should help drive sales among an increasingly eco-conscious customer base."

Article by Susannah Streeter, senior investment and markets analyst, Hargreaves Lansdown


About Hargreaves Lansdown

Over 1.67 million clients trust us with £138.0 billion (as at 30 September 2021), making us the UK’s number one platform for private investors. More than 98% of client activity is done through our digital channels and over 600,000 access our mobile app each month.

Updated on

Jacob Wolinsky is the founder of ValueWalk.com, a popular value investing and hedge fund focused investment website. Jacob worked as an equity analyst first at a micro-cap focused private equity firm, followed by a stint at a smid cap focused research shop. Jacob lives with his wife and four kids in Passaic NJ. - Email: jacob(at)valuewalk.com - Twitter username: JacobWolinsky - Full Disclosure: I do not purchase any equities anymore to avoid even the appearance of a conflict of interest and because at times I may receive grey areas of insider information. I have a few existing holdings from years ago, but I have sold off most of the equities and now only purchase mutual funds and some ETFs. I also own a few grams of Gold and Silver
Previous article Czech Central Bank Delivers Larger Hike – OANDA
Next article Battery Shortage In 2022

No posts to display